Longeveron (LGVN) Gains from Investment Securities (2020 - 2026)
Longeveron (LGVN) recorded quarterly Gains from Investment Securities of $200000.0 in Q1 2026, down 23.08% quarter-over-quarter from $260007.0 in Q4 2025, and up 373.93% on a YoY basis from $42200.0 in Q1 2025.
Longeveron (LGVN) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Longeveron's Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $200000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 373.93% year-over-year to $200000.0; the TTM figure through Mar 2026 stood at $200000.0 (up 373.93% YoY), while the FY2025 annual figure was $260007.0, up 82.71% from the prior year.
- Gains from Investment Securities was $200000.0 for Q1 2026 at Longeveron, down from $260007.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $260007.0 in Q4 2025 to a low of -$12000.0 in Q4 2022.
- Historically, Gains from Investment Securities has averaged $84118.7 across 5 years, with a median of $50000.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities sank 102.71% in 2022, then jumped 577.65% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$12000.0 in 2022, then soared by 275.0% to $21000.0 in 2023, then surged by 577.65% to $142306.0 in 2024, then jumped by 82.71% to $260007.0 in 2025, then dropped by 23.08% to $200000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $200000.0 (Q1 2026), $260007.0 (Q4 2025), and $2820.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 260,007.00 |
| Dec 31, 2025 | 260,007.00 |
| Sep 30, 2025 | 2,820.00 |
| Sep 30, 2025 | 2,820.00 |
| Jun 30, 2025 | 1,700.00 |
| Jun 30, 2025 | 1,700.00 |
| Mar 31, 2025 | 42,200.00 |
| Mar 31, 2025 | 42,200.00 |
| Dec 31, 2024 | 142,306.00 |
| Dec 31, 2024 | 142,306.00 |
| Sep 30, 2024 | 88,625.00 |
| Sep 30, 2024 | 88,625.00 |
| Jun 30, 2024 | 30,200.00 |
| Jun 30, 2024 | 30,200.00 |
| Mar 31, 2024 | 37,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2023 | 21,000.00 |